Variable name;level;Overall;Yes;No;p;test
;n;262;83;179;;
Age;[0 -30);63;16 (25.4);47 (74.6);0.219;
;[30 -35);119;35 (29.4);84 (70.6);;
;[35 -40);76;31 (40.8);45 (59.2);;
;40+;4;1 (25);3 (75);;
Number of children;0;177;55 (31.1);122 (68.9);0.932;
;1;53;17 (32.1);36 (67.9);;
;More than 1;32;11 (34.4);21 (65.6);;
BMI;<18.5;16;11 (68.8);5 (31.2);0.011;
;25-29.9;46;12 (26.1);34 (73.9);;
;>=30;12;3 (25);9 (75);;
;18.5-24.9;181;55 (30.4);126 (69.6);;
Treatment center;Curie Paris;168;52 (31);116 (69);0.842;
;Curie St Cloud;94;31 (33);63 (67);;
Hereditary predisposition;No;159;46 (28.9);113 (71.1);0.563;
;Yes;46;16 (34.8);30 (65.2);;
Inflammatory BC;No;260;83 (31.9);177 (68.1);0.838;
;Yes;2;0 (0);2 (100);;
Clinical Tumor size (mm);;32.0 (20.2);21.8 (13.9);36.6 (20.9);<0.001;
Clinical N stage (TNM);N0;165;61 (37);104 (63);0.017;
;N1;96;21 (21.9);75 (78.1);;
SBR grade;Grade I;11;3 (27.3);8 (72.7);0.623;
;Grade II;96;34 (35.4);62 (64.6);;
;Grade III;154;46 (29.9);108 (70.1);;
Histological type;Lobular;6;3 (50);3 (50);0.204;
;NST;249;76 (30.5);173 (69.5);;
;Others;7;4 (57.1);3 (42.9);;
Neoajuvant chemotherapy;No;118;77 (65.3);41 (34.7);<0.001;
;Yes;144;6 (4.2);138 (95.8);;
Chemotherapy setting;Adjuvant;118;77 (65.3);41 (34.7);<0.001;
;NAC;144;6 (4.2);138 (95.8);;
Fertility preservation discussion;No;3;1 (33.3);2 (66.7);1.000;
;Yes;259;82 (31.7);177 (68.3);;
